These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 1626557

  • 21. Cholestatic Drug-Induced Liver Injury in a Patient Taking High-Dose Niacin for Hyperlipidemia.
    Nawaz N, Mistretta T, Karime C, Lewis J, Wolf E.
    J Investig Med High Impact Case Rep; 2024; 12():23247096231224349. PubMed ID: 38193433
    [Abstract] [Full Text] [Related]

  • 22. A case for immediate-release niacin.
    Bassan M.
    Heart Lung; 2012; 41(1):95-8. PubMed ID: 21414665
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.
    Mullin GE, Greenson JK, Mitchell MC.
    Ann Intern Med; 1989 Aug 01; 111(3):253-5. PubMed ID: 2665592
    [No Abstract] [Full Text] [Related]

  • 26. Safety and side effects of sustained-release niacin.
    Lavie CJ, Milani RV.
    JAMA; 1994 Aug 17; 272(7):513-4; author reply 514-5. PubMed ID: 8046796
    [No Abstract] [Full Text] [Related]

  • 27. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M, Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group.
    Am J Cardiol; 2004 Aug 01; 94(3):306-11. PubMed ID: 15276093
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
    Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM, Zhao XQ, Albers JJ, Knopp RH.
    Am J Cardiol; 1997 Jul 15; 80(2):111-5. PubMed ID: 9230143
    [Abstract] [Full Text] [Related]

  • 30. The bioavailability of sustained release nicotinic acid formulations.
    Neuvonen PJ, Roivas L, Laine K, Sundholm O.
    Br J Clin Pharmacol; 1991 Oct 15; 32(4):473-6. PubMed ID: 1958442
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A clinical trial of oat bran and niacin in the treatment of hyperlipidemia.
    Keenan JM, Wenz JB, Ripsin CM, Huang Z, McCaffrey DJ.
    J Fam Pract; 1992 Mar 15; 34(3):313-9. PubMed ID: 1541958
    [Abstract] [Full Text] [Related]

  • 33. Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction.
    Kristensen T, Olcott EW.
    J Comput Assist Tomogr; 1999 Mar 15; 23(2):314-7. PubMed ID: 10096345
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Niacin and hepatic failure.
    Knopp RH.
    Ann Intern Med; 1989 Nov 01; 111(9):769. PubMed ID: 2802441
    [No Abstract] [Full Text] [Related]

  • 36. Important considerations for treatment with dietary supplement versus prescription niacin products.
    Backes JM, Padley RJ, Moriarty PM.
    Postgrad Med; 2011 Mar 01; 123(2):70-83. PubMed ID: 21474895
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans.
    Gray DR, Morgan T, Chretien SD, Kashyap ML.
    Ann Intern Med; 1994 Aug 15; 121(4):252-8. PubMed ID: 7741833
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Adverse effects of sustained-release niacin.
    Knapp TR, Middleton RK.
    DICP; 1991 Mar 15; 25(3):253-4. PubMed ID: 2028632
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.